奥拉生物科技

US · AURA #3544 按市值排名上市于 2021

6.10 -0.24 -3.79%

实时 - 追踪5344个代码 - 心跳于179秒前 · 2026-10-16 19:30

✦ 量化股权信号计算方式说明

增持

最近一期（2026/Q3）披露持股的机构数量减少了1家。
机构持股总比例上升了0.7个百分点。

机构持股

机构持股比例: 94.23% +0.74pp
机构数量: 178 -1
数据截至: 2026/Q3 较上一报告期

持股变动 vs 资金流向

方向分歧

机构在上一报告期增持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向出现分歧。

机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。

持股人类型

Hedge Fund35.67%

VC/PE Fund33.82%

Mutual Fund23.59%

Individual/Insider1.20%

Public Company0.69%

Private Company0.27%

Other4.57%

主要股东截至 2026-06-30

TCG Crossover Management, LLC 9.19% · 9.53M 股

Montanova Capital, LLC 6.95% · 7.21M 股

Frazier Life Sciences Management, LP 5.62% · 5.83M 股

Forbion Capital Partners B.V. 5.06% · 5.25M 股

Long Focus Capital Management LLC 4.94% · 5.12M 股

Vanguard Capital Management, LLC 4.57% · 4.74M 股

BlackRock 4.54% · 4.71M 股

Adage Capital Management, L.P. 4.47% · 4.64M 股

Caligan Partners, LP 4.14% · 4.30M 股

OrbiMed Advisors LLC 3.21% · 3.33M 股

条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。

内部人持股

共追踪50份申报 · 35次买入 · 15次卖出

姓名	职务	持股比例
David Johnson	Independent Chairperson	0.32%
Elisabet de los Pinos	Chief Executive Officer	0.27%
Mark Plavsic	Chief Technology Officer	0.24%
Amy Elazzouzi	Interim Principal Financial Officer & Interim Principal Accounting Officer	0.14%
Anthony Gibney	Chief Financial & Business Officer	0.08%
J. Hopkins	Chief Medical Officer & President of Research and Development	0.06%
Conor Kilroy	General Counsel	0.04%
Sapna Srivastava	Independent Director	0.02%
Antony Mattessich	Independent Director	0.02%
Julie Feder	Chief Financial Officer	0.02%

内部人交易最近的 Form 4 申报记录

日期	姓名	职务	类型	股数	价格
2026-08-31	Julie Person	Chief Human Resources Officer	Other Acquisition	+107,611	--
2026-08-31	Julie Person	Chief Human Resources Officer	Other Derivative Acquisition	+212,389	$7.43
2026-08-31	Erica Kratz	Chief Regulatory & Quality Officer	Other Acquisition	+100,885	--
2026-08-31	Erica Kratz	Chief Regulatory & Quality Officer	Other Derivative Acquisition	+199,115	$7.43
2026-08-31	J. Hopkins	Chief Medical Officer & President of Research and Development	Other Acquisition	+58,850	--
2026-08-31	J. Hopkins	Chief Medical Officer & President of Research and Development	Other Derivative Acquisition	+116,150	$7.43
2026-08-31	Amy Elazzouzi	Interim Principal Financial Officer & Interim Principal Accounting Officer	Other Acquisition	+23,540	--
2026-08-31	Amy Elazzouzi	Interim Principal Financial Officer & Interim Principal Accounting Officer	Other Derivative Acquisition	+46,460	$7.43
2026-07-06	Jeremy Bender	Independent Director	Other Acquisition	+30,000	--
2026-07-06	Jeremy Bender	Independent Director	Other Derivative Acquisition	+60,000	$7.03
2026-06-30	Conor Kilroy	General Counsel	Other Acquisition	+14,858	--
2026-06-15	Anthony Gibney	Chief Financial & Business Officer	Open Market Disposition	-12,824	$6.42
2026-06-10	Sapna Srivastava	Independent Director	Other Acquisition	+15,000	--
2026-06-10	Sapna Srivastava	Independent Director	Other Derivative Acquisition	+30,000	$6.21
2026-06-10	Antony Mattessich	Independent Director	Other Acquisition	+15,000	--
2026-06-10	Antony Mattessich	Independent Director	Other Derivative Acquisition	+30,000	$6.21
2026-06-10	David Johnson	Independent Chairperson	Other Acquisition	+15,000	--
2026-06-10	David Johnson	Independent Chairperson	Other Derivative Acquisition	+30,000	$6.21
2026-06-10	Teresa Marie Bitetti	Director	Other Acquisition	+15,000	--
2026-06-10	Teresa Marie Bitetti	Director	Other Derivative Acquisition	+30,000	$6.21

Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。

报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。